Sponsor Dossier
Dr Reddys Laboratories
Sponsor Dossier for Dr Reddys Laboratories. ARTG portfolio, PBS-listed brands, PBAC activity, AusPAR record — compiled by arcimedes.
- Brand: ABIRATERONE
- Brand: ABIRATERONE-DRLA
- Brand: ABIRATERONE-REDDY'S
- Brand: ACLONAT
- Brand: AMCAL
- Brand: APO-TERIFLUNOMIDE
- Brand: APX-ELTROMBOPAG
- Brand: APX-SILDENAFIL
About
Dr Reddys Laboratories is an Australian Private Company with ABN 16 120 092 408, registered in Victoria. The company is currently active.
Portfolio
Dr Reddys Laboratories has 107 brands on the ARTG, of which 48 are indexable and 39 carry a Product Information document. 34 brands are PBS-listed, 7 have a PBAC outcome on record, and 5 have an AusPAR on record. Notable brands include ABIRATERONE, ABIRATERONE-DRLA, ABIRATERONE-REDDY'S, ACLONAT, AMCAL, APO-TERIFLUNOMIDE, APX-ELTROMBOPAG, APX-SILDENAFIL, ARX-ABIRATERONE, ARX-IMATINIB, ARX-SEVELAMER, AZACITIDINE.
Therapeutic focus
— Oncology: 39 brands — Neurology: 13 brands — Haematology: 8 brands — Reproductive Health: 7 brands — Cardiology: 7 brands — Infectious Disease: 6 brands — Respiratory: 5 brands — Musculoskeletal: 4 brands — Renal: 4 brands — Rare Disease: 4 brands — Dermatology: 3 brands — Other: 2 brands — Immunology: 2 brands — Pain Management: 1 brand — Psychiatry: 1 brand — Gastroenterology: 1 brand
PBS footprint
34 brands are PBS-listed, with the latest PBS schedule date 2026-10-01.
Regulatory activity
The latest PBAC outcome is 2025-07-01, across 7 brands with a PBAC outcome on record. The latest AusPAR is 2026-07-07, across 5 brands with an AusPAR on record.